Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model

Nature Medicine volume 4, pages 1438–1440 (1998)Cite this article

Abstract

Live virus vaccines have in many cases proven to be an extremely effective tool for the prevention of viral diseases 1, 2 . However, the production of conventional live vaccines in eukaryotic cell cultures has many disadvantages, including the potential for contamination with adventitious agents 3 and genetic alterations during propagation, making it necessary to do extensive testing before distribution 4, 5 . Based on results obtained with a flavivirus 6 (tick-borne encephalitis virus) in an experimental animal system, we propose a novel live attenuated virus vaccination strategy consisting of the application of in vitro -synthesized infectious RNA instead of the live virus itself. When administered using the GeneGun, less than 1 ng of RNA was required to initiate replication of virus that was attenuated by a specifically engineered deletion 7 and this induced a protective immunity in laboratory mice. Because this approach uses RNA, it does not have the potential drawbacks of DNA vaccines 8, 9, 10 and thus combines the advantages of conventional live virus vaccines 1, 2 (for example, mimicking natural infection and inducing long-lasting immunity) with those of nucleic acid-based vaccines 2, 8, 11, 12 (for example, ease of production without a requirement for eukaryotic cell culture, stability and purity).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ada, G. Overview of vaccines. Mol. Biotechnol. 8, 123– 134 (1997).

    Article  CAS  Google Scholar 

  2. Liu, M.A. Vaccine developments. Nature Med. 4, 515–519 (1998).

    Article  CAS  Google Scholar 

  3. Petricciani, J.C. Regulatory philosophy and acceptability of cells for the production of biologicals. Dev. Biol. Stand. 75, 9– 15 (1991).

    CAS  PubMed  Google Scholar 

  4. Parkman, P.D. & Hardegree, M.C. in Vaccines 2nd edn. (eds. Plotkin, S.A. & Mortimer, E.A.) 889– 901 (W.B. Saunders, Philadelphia, Pennsylvania, 1994).

    Google Scholar 

  5. Wood, D.J. & Macadam, A.J. Laboratory tests for live attenuated poliovirus vaccines. Biologicals 25, 3– 15 (1997).

    Article  CAS  Google Scholar 

  6. Wengler, G. et al. in Virus Taxonomy. Sixth Report of the International Committee on Taxonomy of Viruses (eds. Murphy, F.A. et al.) 415– 427 (Springer-Verlag, Vienna, Austria,1995).

    Google Scholar 

  7. Mandl, C.W. et al. Spontaneous and engineered deletion in the 3´ noncoding region of tick-borne encephalitis virus: Construction of highly attenuated mutants of a flavivirus. J. Virol. 72, 2132–2140 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Vogel, F.R. & Sarver, N. Nucleic acid vaccines. Clin. Microbiol. Rev. 8, 406–410 (1995).

    Article  CAS  Google Scholar 

  9. Manickan, E., Karem, K.L. & Rouse, B.T. DNA vaccines – a modern gimmick or a boon to vaccinology? Crit. Rev. Immunol. 17, 139–154 (1997).

    Article  CAS  Google Scholar 

  10. Gregoriadis, G. Genetic vaccines: strategies for optimization. Pharm. Res. 15, 661–670 (1998).

    Article  CAS  Google Scholar 

  11. Donnelly, J.J., Ulmer, J.B., Shiver, J.W. & Liu, M.A. DNA vaccines. Annu. Rev. Immunol. 15, 617–648 (1997).

    Article  CAS  Google Scholar 

  12. Chattergoon, M., Boyer, J. & Weiner, D.B. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J. 11, 753– 763 (1997).

    Article  CAS  Google Scholar 

  13. Rice, C.M. in Fields Virology, 3rd edn. (eds. Fields, B.N. et al. ) 931–960 (Lippincott-Raven, Philadelphia, Pennsylvania, 1996).

    Google Scholar 

  14. Mandl, C.W., Ecker, M., Holzmann, H., Kunz, C. & Heinz, F.X. Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr. J. Gen. Virol. 78, 1049– 1057 (1997).

    Article  CAS  Google Scholar 

  15. Conry, R.M., LoBuglio, A.F. & Curiel, D.T. Polynucleotide-mediated immunization therapy of cancer. Semin. Oncol. 23, 135– 147 (1996).

    CAS  PubMed  Google Scholar 

  16. Nair, S.K. et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364– 369 (1998).

    Article  CAS  Google Scholar 

  17. Qiu, P., Ziegelhoffer, P., Sun, J. & Yang, N.S. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther. 3, 262–268 (1996).

    CAS  PubMed  Google Scholar 

  18. Zhou, X. et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12, 1510–1514 (1994).

    Article  CAS  Google Scholar 

  19. Heinz,, F.X., Tuma, W., Guirakhoo, F. & Kunz, C. A model study of the use of monoclonal antibodies in capture enzyme immunoassays for antigen quantification exploiting the epitope map of tick-borne encephalitis virus. J. Biol. Standard. 14, 133– 141 (1986).

    Article  CAS  Google Scholar 

  20. Reed, J.L. & Muench, H. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27, 493 (1938).

    Google Scholar 

Download references

Acknowledgements

We thank H. Dippe and M. Wilfinger for their technical assistance.

Author information

Authors and Affiliations

  1. Institute of Virology, University of Vienna, Vienna, Austria

    Christian W. Mandl, Judith H. Aberle, Stephan W. Aberle, Heidemarie Holzmann, Steven L. Allison & Franz X. Heinz

Authors
  1. Christian W. Mandl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judith H. Aberle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephan W. Aberle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heidemarie Holzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steven L. Allison
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Franz X. Heinz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian W. Mandl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mandl, C., Aberle, J., Aberle, S. et al. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med 4, 1438–1440 (1998). https://doi.org/10.1038/4031

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/4031

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing